PMID- 12975539
OWN - NLM
STAT- MEDLINE
DCOM- 20040121
LR  - 20171101
IS  - 0008-6312 (Print)
IS  - 0008-6312 (Linking)
VI  - 100
IP  - 1
DP  - 2003
TI  - Elevated serum CA 125 levels in mitral stenotic patients with heart failure.
PG  - 7-10
AB  - BACKGROUND: Elevated tumor marker levels have been reported in heart failure 
      patients with left ventricular (LV) systolic dysfunction and enlargement. The 
      levels of several tumor markers, including CA 125, CA 19-9, CA 15-3 and CEA, in 
      rheumatic mitral stenotic patients were compared to the control group. MATERIALS 
      AND METHODS: Tumor markers were measured in 60 mitral stenotic patients and in 30 
      normal subjects who served as the control group. Mitral stenotic patients were 
      classified into two categories of cardiac dysfunction based on the classification 
      of the New York Heart Association (NYHA). Group I consisted of 31 patients in 
      NYHA class 3-4 and group II of 29 patients in NYHA class 1-2. Echocardiographic 
      examinations and invasive hemodynamic monitoring were performed in all patients. 
      RESULTS: Group I patients had decreased mitral valve area (p = 0.004) and higher 
      left atrial diameter (p = 0.003) than group II patients. Right atrial, mean 
      pulmonary artery and pulmonary capillary wedge pressures and transmitral gradient 
      were higher in group I than in group II (p = 0.010, 0.0001, 0.0001 and 0.0001, 
      respectively). CA 125 levels were statistically higher in mitral stenotic patient 
      groups than in the control group (p < 0.0001). No statistically significant 
      differences were shown for the other tumor markers. Group I patients had higher 
      CA 125 levels compared to group II (p < 0.0001). CONCLUSION: Elevated CA 125 
      levels may be due to venous congestion and activation of peritoneal mesothelium 
      or increased signal peptides.
CI  - Copyright 2003 S. Karger AG, Basel
FAU - Duman, Can
AU  - Duman C
AD  - Department of Biochemistry, Kocaeli University, Kocaeli, Turkey.
FAU - Ercan, Ertugrul
AU  - Ercan E
FAU - Tengiz, Istemihan
AU  - Tengiz I
FAU - Bozdemir, Huseyin
AU  - Bozdemir H
FAU - Ercan, H Ekin
AU  - Ercan HE
FAU - Nalbantgil, Istemi
AU  - Nalbantgil I
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-125 Antigen)
SB  - IM
MH  - Biomarkers, Tumor/*blood
MH  - CA-125 Antigen/*blood
MH  - Cardiac Output, Low/*blood/complications/diagnostic imaging
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Stenosis/*blood/complications/diagnostic imaging
MH  - Prospective Studies
MH  - Risk Factors
MH  - Ultrasonography
EDAT- 2003/09/17 05:00
MHDA- 2004/01/22 05:00
CRDT- 2003/09/17 05:00
PHST- 2002/11/23 00:00 [received]
PHST- 2003/05/05 00:00 [accepted]
PHST- 2003/09/17 05:00 [pubmed]
PHST- 2004/01/22 05:00 [medline]
PHST- 2003/09/17 05:00 [entrez]
AID - 72385 [pii]
AID - 10.1159/000072385 [doi]
PST - ppublish
SO  - Cardiology. 2003;100(1):7-10. doi: 10.1159/000072385.